TANIA ABOUSAID: Open Payments
NPI 1295317725 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 59 payments from 16 companies in 2025. Trend: 2023 $940 · 2024 $1,229 · 2025 $1,211
Food & beverage: $1,211
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $370 |
| Novo Nordisk Inc | 9 | $206 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| GENZYME CORPORATION | 3 | $84 |
| GlaxoSmithKline, LLC. | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Hologic Sales and Service, LLC | 2 | $43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
Products named: QULIPTA, DUPIXENT, Ozempic, Rybelsus, UBRELVY, BREZTRI, VRAYLAR, TRELEGY ELLIPTA.
Industry payments across NY — which companies pay providers there.
